Checkpoint Therapeutics, Inc. (CKPT)
4.260
0.00 (0.00%)
Inactive · Last trade price on May 29, 2025
Checkpoint Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 33.04 | 6.6 | 4.93 | 12.07 | 54.74 | 40.77 |
Cash & Short-Term Investments | 33.04 | 6.6 | 4.93 | 12.07 | 54.74 | 40.77 |
Cash Growth | 193.94% | 34.01% | -59.16% | -77.95% | 34.25% | 56.35% |
Receivables | - | - | - | 0.07 | 0.02 | 0.02 |
Prepaid Expenses | 1.12 | 0.87 | 0.45 | 1.15 | 0.98 | 1.8 |
Total Current Assets | 34.16 | 7.47 | 5.38 | 13.29 | 55.73 | 42.6 |
Total Assets | 34.16 | 7.47 | 5.38 | 13.29 | 55.73 | 42.6 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 14.74 | 6.09 | 6.57 | 11.54 | 16.14 | 3.44 |
Accrued Expenses | 2.87 | 12.35 | 11.14 | 9.79 | 9.61 | 3.39 |
Other Current Liabilities | 0.26 | 1.66 | 0.71 | 11.45 | 0.23 | 0.39 |
Total Current Liabilities | 17.87 | 20.1 | 18.43 | 32.77 | 25.98 | 7.22 |
Total Liabilities | 17.87 | 20.1 | 18.43 | 32.77 | 25.98 | 7.22 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | 0.01 |
Additional Paid-In Capital | 398.07 | 350.31 | 297.86 | 241.12 | 223.01 | 173.95 |
Retained Earnings | -381.79 | -370.57 | -314.33 | -262.49 | -199.86 | -143.19 |
Comprehensive Income & Other | - | 7.64 | 3.42 | 1.89 | 6.6 | 4.62 |
Shareholders' Equity | 16.3 | -12.63 | -13.05 | -19.48 | 29.75 | 35.38 |
Total Liabilities & Equity | 34.16 | 7.47 | 5.38 | 13.29 | 55.73 | 42.6 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Cash (Debt) | 33.04 | 6.6 | 4.93 | 12.07 | 54.74 | 40.77 |
Net Cash Growth | 193.94% | 34.01% | -59.16% | -77.95% | 34.25% | 56.35% |
Net Cash Per Share | 0.71 | 0.17 | 0.18 | 1.17 | 6.47 | 7.30 |
Filing Date Shares Outstanding | 83.06 | 83.76 | 35.69 | 12.95 | 9.06 | 7.52 |
Total Common Shares Outstanding | 83.06 | 54.34 | 27.74 | 10.29 | 8.46 | 6.94 |
Working Capital | 16.3 | -12.63 | -13.05 | -19.48 | 29.75 | 35.38 |
Book Value Per Share | 0.20 | -0.23 | -0.47 | -1.89 | 3.52 | 5.10 |
Tangible Book Value | 16.3 | -12.63 | -13.05 | -19.48 | 29.75 | 35.38 |
Tangible Book Value Per Share | 0.20 | -0.23 | -0.47 | -1.89 | 3.52 | 5.10 |